 | • レポートコード：MRC2304F087 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、230ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本市場調査資料では、世界の利尿薬市場規模が、2021年に1,019.49百万ドル、2022年に1,103.75百万ドルになり、その後CAGR 8.44％で成長して2027年までに1,657.97百万ドルに達すると予測しています。本書は、利尿薬の世界市場を対象とした調査・分析結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬剤種類別分析（カルシウム節約利尿剤、炭酸脱水酵素阻害剤、ループ利尿薬、浸透圧利尿薬、カリウム保持性利尿薬）、投与経路別分析（静脈内、経口）、用途別分析（尿崩症、浮腫、高カルシウム尿症、高血圧症）、流通チャネル別分析（病院薬局、オンライン薬局、小売薬局）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの内容を掲載しています。なお、本書内の企業情報には、Abbott Laboratories、AbbVie Inc.、Alembic Pharmaceuticals Limited、Amneal Pharmaceuticals LLC、Aurobindo Pharma Limited、Bausch Health Companies Inc.、Centaur Pharmaceuticals Pvt Ltd、Cipla Ltd、Endo Pharmaceuticals Inc、Hikma Pharmaceuticals Inc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の利尿薬市場規模：薬剤種類別 - カルシウム節約利尿剤の市場規模 - 炭酸脱水酵素阻害剤の市場規模 - ループ利尿薬の市場規模 - 浸透圧利尿薬の市場規模 - カリウム保持性利尿薬の市場規模 ・世界の利尿薬市場規模：投与経路別 - 静脈内投与の市場規模 - 経口投与の市場規模 ・世界の利尿薬市場規模：用途別 - 尿崩症における市場規模 - 浮腫における市場規模 - 高カルシウム尿症における市場規模 - 高血圧症における市場規模 ・世界の利尿薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界の利尿薬市場規模：地域別 - 南北アメリカの利尿薬市場規模 アメリカの利尿薬市場規模 カナダの利尿薬市場規模 ブラジルの利尿薬市場規模 ... - アジア太平洋の利尿薬市場規模 日本の利尿薬市場規模 中国の利尿薬市場規模 インドの利尿薬市場規模 韓国の利尿薬市場規模 台湾の利尿薬市場規模 ... - ヨーロッパ/中東/アフリカの利尿薬市場規模 イギリスの利尿薬市場規模 ドイツの利尿薬市場規模 フランスの利尿薬市場規模 ロシアの利尿薬市場規模 ... - その他地域の利尿薬市場規模 ・競争状況 ・企業情報 |
The Global Diuretics Drugs Market size was estimated at USD 1,019.49 million in 2021 and expected to reach USD 1,103.75 million in 2022, and is projected to grow at a CAGR 8.44% to reach USD 1,657.97 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Diuretics Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Type, the market was studied across Calcium Sparing Diuretics, Carbonic Anhydrase Inhibitors, Loop Diuretics, Low Ceiling Diuretics, Osmotic Diuretics, Potassium-Sparing Diuretics, and Thiazide Diuretics Local.
Based on Route of Administration, the market was studied across Intravenous and Oral.
Based on Applications, the market was studied across Diabetes Insipidus, Edema, Hypercalciuria, and Hypertension.
Based on Distribution Channel, the market was studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Diuretics Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Diuretics Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Diuretics Drugs Market, including Abbott Laboratories, AbbVie Inc., Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, Bausch Health Companies Inc., Centaur Pharmaceuticals Pvt Ltd, Cipla Ltd, Endo Pharmaceuticals Inc, Hikma Pharmaceuticals Inc., Meda Manufacturing GmbH, Merck & Co., Inc., Mylan N.V., Novartis International AG, Paddock Laboratories, LLC, Perrigo Pharmaceuticals Company, Pfizer Inc, Sandoz International GmbH, Sanofi-aventis U.S. LLC, Sun Pharmaceuticals Industries Ltd, Teva Pharmaceutical Industries Ltd., Upsher-Smith Laboratories, LLC., Validus Pharmaceuticals LLC, and Zydus Cadila.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Diuretics Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Diuretics Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Diuretics Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Diuretics Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Diuretics Drugs Market?
6. What is the market share of the leading vendors in the Global Diuretics Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Diuretics Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of renal and kidney disorders worldwide owing to changing consumer lifestyles
5.1.1.2. Growing geriatric populace globally
5.1.1.3. Surge in the number of cardiovascular disorders globally
5.1.2. Restraints
5.1.2.1. Risks associated with negative impact on patients if discontinued
5.1.3. Opportunities
5.1.3.1. Technological development and introduction of new therapies
5.1.3.2. Increasing mergers and acquisition to increase the product awareness and availability
5.1.4. Challenges
5.1.4.1. Strict regulations and compliance by regulatory bodies
5.2. Cumulative Impact of COVID-19
6. Diuretics Drugs Market, by Drug Type
6.1. Introduction
6.2. Calcium Sparing Diuretics
6.3. Carbonic Anhydrase Inhibitors
6.4. Loop Diuretics
6.5. Low Ceiling Diuretics
6.6. Osmotic Diuretics
6.7. Potassium-Sparing Diuretics
6.8. Thiazide Diuretics Local
7. Diuretics Drugs Market, by Route of Administration
7.1. Introduction
7.2. Intravenous
7.3. Oral
8. Diuretics Drugs Market, by Applications
8.1. Introduction
8.2. Diabetes Insipidus
8.3. Edema
8.4. Hypercalciuria
8.5. Hypertension
9. Diuretics Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Drug Stores
9.3. Hospital Pharmacies
9.4. Online Pharmacies
9.5. Retail Pharmacies
10. Americas Diuretics Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Diuretics Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Diuretics Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abbott Laboratories
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. AbbVie Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Alembic Pharmaceuticals Limited
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Amneal Pharmaceuticals LLC
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Aurobindo Pharma Limited
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Bausch Health Companies Inc.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Centaur Pharmaceuticals Pvt Ltd
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Cipla Ltd
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Endo Pharmaceuticals Inc
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Hikma Pharmaceuticals Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Meda Manufacturing GmbH
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Merck & Co., Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Mylan N.V.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Novartis International AG
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Paddock Laboratories, LLC
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Perrigo Pharmaceuticals Company
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Pfizer Inc
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Sandoz International GmbH
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Sanofi-aventis U.S. LLC
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Sun Pharmaceuticals Industries Ltd
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Teva Pharmaceutical Industries Ltd.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Upsher-Smith Laboratories, LLC.
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Validus Pharmaceuticals LLC
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. Zydus Cadila
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing